February 25, 2017 1:21pm

 

Change is needed …

It’s hard not to be provocative or rant as reality and truths come to light!  

 

What happened, what did it all mean and why was it important in today’s sector outcomes

Investors are fed-up with the lack of sustainable appreciation …

Especially as incompetence is too frequently rewarded with severance packages

 

I answer one question, short and without sweeteners; in which company should investors put, keep and commit their money

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds, and just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

U.S. equities closed flat to higher Friday, taking a breath from their most recent run at record levels, while investors awaited President Donald Trump's speech to Congress next week.

The NASDAQ closed UP +9.80 or +0.17% to 5845.31 and the DOW closed UP +11.44 or +0.05% to 20,821.76.

 

 

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

  • The open was negative with an A/DL of 7/30 and 6 flats;
  • The mid-day stayed negative with an A/DL of 15/25 and 3 flats;
  • The close continued negative with an A/DL of 17/23 and 3 flats;

 

 

Henry’omics:

The stem, cell, gene and regenerative sector and the stock markets are sending conflicting signals about the outlook for “our’ universe.

  • The sector is out of gas, lacking GPS and a destination for their development programs.

Investors aren’t hearing the stories of advancement as many clinical studies are about to blown away by small patient population data points making … a P2 or P3’s trial more about another maybe!

  • The CBOE Volatility Index, the “fear index” has remained relatively subdued—yet “our’ universe reverberates <I believe> at a 3X factor versus the market on the whole.

Investors need to show a number of current CEOs and their syncopated management teams to the door … if some of these companies are to survive in any shape or form.

  • How many different stories are six to nine months old with promised results still NOT published, peer reviewed or even alluded to by “some’ companies.

I am also waiting for some sector micro-cap company’s financial results which are more than likely to be – UGLY.

  • Yet, many of these same companies will SPIN their results noticing regulatory concerns versus the true incompetence of their clinical initiatives …

The questions investors should be asking … why weren’t we as investors made aware of pre-clinical short-coming or as I call them - irregularities?

  • Did CEOs just think they could JUST overcome them, and that’s why they didn’t update their guidance because they … NEVER issued ANY?

What should investors think about a company’s execution which has NOT been defined or communication …?

 

I say EXPOSE the PARASITES infecting our portfolios!!

 

 

My pet peeve:

High-frequency trading accounted for 52% of February's daily trading volume of about 6.81 billion shares <TABB Group>.

  • During the peak levels of high-frequency trading in 2009, about 61% of 9.8 billion of average daily shares traded were executed by high-frequency traders.

 

 

Indexes, the ebb and flow:

  • The iShares Russell 2000 (IWM) closed DOWN -0.07%
  • The iShares NASDAQ Biotechnology (IBB) closed UP +0.20%

 

 

The downside shows a pricing trend of:

  • Friday’s decliners ranged from -0.54% <XON> to -6.73% <RENE.L> in 23 equities;
  • Thursday – family death;
  • Wednesday’s decliners ranged from -0.00% <KOOL> to -6.81% <OSIR> in 27 equities;
  • Tuesday’s decliners ranged from -0.17% <JUNO> to -5.63% <FCSC> in 21 equities;
  • Monday, the market was closed;
  • Last Friday’s decliners ranged from -0.12% <ONCE> to -7.06% <NWBO> in 17 equities;

 

The upside shows a pricing trend of:

  • Friday’s gainers ranged from +0.17% <KOOL> to +6.20% <STML> in 17equities;
  • Thursday – family death;
  • Wednesday’s gainers ranged from +0.39% <CLBS> to +14.47% <BCLI> in 14 equities;
  • Tuesday’s gainers ranged from +0.34% <ONCE> to +11.94% <BSTG> in 17 equities;
  • Monday, the market was closed;
  • Last Friday’s gainers ranged from +0.24% <MDXG> to +15.93% <FATE> in 24 equities;

 

 

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Friday traded near 11.4;

·         Thursday traded near 11.7;

·         Wednesday traded near 11.8;

·         Tuesday traded near 11.8;

·         Monday was a holiday;

·         Last Friday traded near 11.5;

                                                                                                                                                                               

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.